5 completed, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow GW Research Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neuroimaging and CBD for Opioid Use Disorder Cannabidiol (CBD), Placebo - Heroin Abuse, Opioid Use Disorder | Phase 2 | Completed | Yasmin Hurd | 66 | 2020-11-12 | 2025-10-27 |
| A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease cannabidiol - Parkinson's Disease | Phase 2 | Completed | University of Colorado, Denver | 13 | 2016-10-01 | 2019-02-19 |
| An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes GWP42003-P - Epilepsy, Dravet Syndrome | Phase 3 | Completed | GW Research Ltd | 681 | 2015-06-11 | 2022-02-03 |
| A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160) GWP42003, Placebo - Ulcerative Colitis | Phase 2 | Completed | GW Research Ltd | 60 | 2012-05-09 | 2018-08-09 |
| Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine GWP42003 : GWP42004 (40:1), Placebo - Schizophrenia | Phase 2 | Terminated | GW Research Ltd | 2 | 2011-10-01 | 2014-09-18 |
| Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease GWP42003 200 mg/day Dose, GWP42003 400 mg/day Dose, GWP42003 800 mg/day Dose - Fatty Liver | Phase 2 | Completed | GW Research Ltd | 25 | 2011-05-03 | 2018-08-08 |
| Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. Sativex, Placebo - Spasticity, Multiple Sclerosis | Phase 3 | Withdrawn | GW Research Ltd | 2016-08-11 |
Anxiety Disorders (1) · Colitis, Ulcerative (1) · Diabetes Mellitus (1) · Dyskinesias (1) · Epilepsies, Myoclonic (1) · Epilepsy (1) · Fatty Liver (1) · Heroin Dependence (1) · Lennox Gastaut Syndrome (1) · Marijuana Abuse (1) · Multiple Sclerosis (1) · Muscle Spasticity (1) · Opioid-Related Disorders (1) · Parkinson Disease (1) · Psychotic Disorders (1)
Cannabidiol (5) · nabiximols (1)
United Kingdom (3) · United States (2)
Maureen A Leehey, M.D. (1) · Yasmin Hurd, PhD (1)
PMID 29538683, PMID 34287833, PMID 34406656
2009 (1), 2014 (1)